Mursla Bio unlocks new biomarker discovery approach in liquid biopsy and precision medicine
Mursla Bio to showcase its novel tissue-specific extracellular vesicle isolation technology at ISEV2023
Mursla gains mentorship support from Roche Diagnostics Ltd for pilot study in cirrhotic and liver cancer patients
Access to Roche Diagnostics’ expertise in the UK secured in recognition of Mursla’s differentiated value proposition for liquid biopsy.
Mursla announces key appointments to Advisory Board
Key opinion leaders in the fields of exosomes, liquid biopsy and liver disease support Mursla’s ambition to bring its integrated platform for the discovery and profiling of exosome phenotypes in diseases to the clinic.
Mursla granted patent for novel nanoelectronics detection system for exosomes
Mursla, a liquid biopsy company, is delighted to announce that it has been granted patent GB 2583550B for its novel nanoelectronics-based sensitive detection method for exosomes. This unique technology harnesses the promising diagnostic power of exosomes and demonstrates its potential application for the detection of many diseases, including cancer.